LSV Asset Management
AUPH icon

LSV Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

LSV Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
1,079,447
+39,871
+4% +$637K 0.03% 356
2026
Q1 		$15.4M Buy
1,039,576
+382,729
+58% +$5.59M 0.03% 347
2025
Q4 		$10.5M Buy
+656,847
New +$9.31M 0.02% 381

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management's AUPH Position: Q2 2026 in Review

LSV Asset Management increased its Aurinia Pharmaceuticals (AUPH) stake by 3.8% in Q2 2026, buying an estimated $637K and bringing the position to 1,079,447 shares worth $18.3M. The position accounts for 0.03% of the portfolio, ranked #356.

LSV Asset Management first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • LSV Asset Management held 1,079,447 shares of Aurinia Pharmaceuticals worth $18.3M as of Q2 2026.
  • LSV Asset Management bought 39,871 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $637K.
  • Aurinia Pharmaceuticals made up 0.03% of LSV Asset Management's portfolio in Q2 2026, its #356 holding.
  • LSV Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.